AMGN trades against a final fair-value range of $366.98-$644.16, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $367, high $644, with mid-point at $505.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$505
Margin of safety
+34.9%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$329.09Price
Low $366.98
Mid $505.34
High $644.16
AMGN trades against a final fair-value range of $366.98-$644.16, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Extensive patent portfolio and regulatory
Extensive patent portfolio and regulatory exclusivity
Manufacturing scale and complexity in
Manufacturing scale and complexity in biologics
Bull thesis
Contrarian: The market's -0.48% growth assumption is overly pessimistic and ignores structural cash power.
Each scenario for AMGN (AMGN) carries a five-year price target, an explicit set of assumptions (growth, terminal multiple, margin path), and a probability weight calibrated against current visibility.
Probability weights start from a 25/50/25 default and are asymmetry-adjusted: when downside risk is elevated, base + bear gain weight; when visibility is high (long RPO, multi-year contracts), bull and base both gain.
Expected return is the probability-weighted average of the three scenario returns. The expected-value table reports the weighted price, weighted return, and asymmetry to help the reader compare risk-reward against the rating band.
When our composite fair value differs from private calibration references by more than 30%, the calibration-divergence diagnostic is run to identify which assumptions drive the gap; the result is summarised in the parent valuation surface.
FAQ
AMGN — frequently asked questions
Based on our latest analysis, AMGN looks meaningfully undervalued. The current price is $329 versus a composite fair-value midpoint of $505 (range $367–$644), which implies roughly 53.6% upside to the midpoint.
Our composite fair-value range for AMGN is $367–$644, with a midpoint of $505. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for AMGN's archetype.
Our current rating for AMGN is Strong Buy with a confidence score of 88/100. AMGN is rated Strong Buy at $329.09 versus the reconciled fair value midpoint of $505.34, implying +53.56% upside/downside. Confidence is separately disclosed at 88/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for AMGN are: MariTide Clinical Failure; Aggressive IRA Pricing; M&A Deleveraging Trap. The single biggest risk is Growth: High-optionality pipeline in obesity offers massive upside not currently priced in.
Our current rating for AMGN is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($367–$644) versus the current price of $329.
AMGN is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for AMGN.